The FDA rejected Capricor’s Duchenne cell therapy deramiocel for a second time, citing “serious data integrity violations” that compromised the company’s study findings. The regulator’s action adds another setback for the late-stage development of a platform aimed at improving cardiac and skeletal muscle function in Duchenne muscular dystrophy. Capricor now faces the task of addressing the specific compliance and data validation issues identified by the agency before resubmission. The second complete rejection highlights how quality-system and evidence-pack issues can be as decisive as clinical results in getting therapies across the finish line. For the wider cell therapy sector, the decision reinforces the scrutiny applied to manufacturing consistency, endpoint reporting, and the defensibility of trial data, particularly when investigational products rely on complex biological processes.
Get the Daily Brief